Adherence rates with infliximab therapy in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 7, 2006, Pages 1099-1103

  Kane, S ^a   Dixon, L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIVARIATE ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APPOINTMENTS AND SCHEDULES; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 33748652466     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03092.x     Document Type: Article

References (14)

1. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333-6.
2. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Predictors of non-compliance with mesalamine in quiesecent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-32.
3. Hanauer SB, Feagan BG, Lichtenstein GR and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
5. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-9.
6. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44.
7. Vemupalli R, Cohen RC, Whiteside L, et al. IBD disproportionately impacts women's professional and personal lives. Am J Gastroenterol, 2006. (in press).
8. Haynes RB. Determinants of compliance: the disease and the mechanisms of treatment. In: Haynes RB, Taynor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979: 12-35.
9. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease. Psychiatry and compliance. J Clin Gastroenterol 2001; 32: 66-8.
10. Sackett DL, Snow JC. The magnitude of compliance and non-compliance. In: Haynes RB, Taylor DT, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979: 11-22.
11. Nobel LM. Doctor-patient communication and adherence to treatment. In: Myers LB, Midence K, eds. Adherence to Treatment in Medical Conditions. New York: Harwood Academic Publishers, 1998: 51-82.
12. Kane SV. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97: 1853.
13. Kane SV, Aikens J, Hanauer SB. Medication regimens are associated with non-adherence in quiescent ulcerative colitis. Am J Gastroenterol 2002; 97: S770.
14. Kane SV, Huo D, Magnanti K. A pilot feasibility trial of once daily vs. conventional dosing of mesalamine for treatment of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-3.